Featured Trial
Clinical Trial Goal
To find out if CIML-NK cells are safe and work well to treat AML that has relapsed or is refractory
You may be able to join this trial if you:
- Are 2 years old or older
- Have AML that has relapsed or is refractory
- Have a half-matched related donor. Your biological parents and children may be a half match for you
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
CIML-NK cells are a type of allogeneic (cells from a donor) immune cell that doctors think will attack and kill cancer cells.
You’ll get:
You’ll get:
- CIML-NK cells – Given as an intravenous (IV) infusion. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 6 months.
The Food and Drug Administration (FDA) has not yet approved CIML-NK cells.
The Food and Drug Administration (FDA) has not yet approved CIML-NK cells.
Contacts
Zahra Hudda, 917-754-7118, Zahra.Hudda@cchmc.org
Caitlin Cottrell, 513-803-7039, Caitlin.cottrell@cchmc.org
Locations
Cincinnati Children's Hospital Medical CenterRECRUITING
Cincinnati, Ohio
Contacts:
- Caitlin Cottrell, Caitlin.cottrell@cchmc.org
- Richard Cooper, richard.cooper@cchmc.org
Sponsors
lead: Children's Hospital Medical Center, Cincinnati
